Loading...
•
Sep 30, 2021
Viridian Therapeutics Q3 2021 Earnings Report
Viridian Therapeutics' financial position was strengthened and pipeline expansion was supported.
Key Takeaways
Viridian Therapeutics reported financial results for the third quarter ended September 30, 2021. The company's cash, cash equivalents and short-term investments were $213.8 million as of September 30, 2021. Net loss was $14.03 million for the quarter.
Submitted an IND application to the FDA for VRDN-001 for Thyroid Eye Disease (TED) treatment.
Expect to report Phase 1/2 proof of concept clinical data in TED patients in Q2 2022.
VRDN-002 remains on track for an IND filing before year end 2021, with initial clinical data expected in mid-2022.
Pro forma cash position of $213.8 million to support company and pipeline expansion, funding operations into 2024.
Viridian Therapeutics
Viridian Therapeutics
Forward Guidance
The company expects to announce top line proof of concept clinical data in the second quarter of 2022 from the trial that includes TED patients in two randomized, placebo-controlled cohorts. Top line data from VRDN-002's Phase 1 single ascending dose trial are expected in mid-year 2022.